Endpoints News

Now that AstraZeneca's megadeal with Bristol Myers seems off the table, its in-house portfolio needs to perform. In the US, it may face more price pressure on its new blood pressure pill Baxfendy, for which it's charging $10,950 a year, as Elizabeth Cairns writes today.

Drew Armstrong

Executive Editor, Endpoints News
@ArmstrongDrew

ICER says AstraZeneca’s new blood pressure med isn’t cost-effective

by Elizabeth Cairns

The drug price watchdog ICER issued a report Thursday concluding that the benefits of AstraZeneca’s new blood pressure pill Baxfendy don’t justify its $10,950 per...

Read the full story

Cytokinetics brings patent suit against Bristol Myers Squibb, escalating rivalry

by Nicole DeFeudis

Cytokinetics and Bristol Myers Squibb are fierce market rivals. Now they’re also rivals in court.

Cytokinetics filed a lawsuit against Bristol Myers on Wednesday...

Read the full story

Biogen's monoclonal antibody felzartamab wins first global approval in China

by Nicole DeFeudis

Biogen’s monoclonal antibody felzartamab was approved in China for the treatment of multiple myeloma.

Felzartamab will be available in China for second-line multiple myeloma patients...

Read the full story

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com

Endpoints Studio
Endpoints Webinars

Endpoints Events
Biopharma Jobs

Worldwide made. Thanks for reading.

Unsubscribe preferences

Unsubscribe from all newsletters